Drug-drug interactions associated with length of stay and cost of hospitalization

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 3, 2009, Pages 266-272

  Moura, Cristiano ^a,b   Acurcio, Francisco ^b   Belo, Najara ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMITRIPTYLINE; CAPTOPRIL; DEXAMETHASONE; DIGOXIN; FUROSEMIDE; KETOPROFEN; PHENYTOIN; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAZIL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG COST; DRUG DRUG INTERACTION; DRUG INTERACTION; FEMALE; HOSPITALIZATION COST; HUMAN; INAPPROPRIATE PRESCRIBING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; POLYPHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; ADOLESCENT; AGED; AGING; HOSPITAL; HOSPITAL COST; MIDDLE AGED; SEXUAL DEVELOPMENT; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; BRAZIL; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FEMALE; HOSPITAL COSTS; HOSPITALS, URBAN; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; POLYPHARMACY; RETROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 77950356618     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j35c7z     Document Type: Article

References (23)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash), 2001; 41:192-9.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA, 1997; 277:301-6.
3. Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, et al. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation, 2001; 49:283-8.
4. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J Clin Pharm Ther, 2005; 30:13-20.
5. Cruciol-Souza JM, Thomson, JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci, 2006; 9:427-33.
6. Glintborg B, Andersen SE, Dalhoff, K. Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant. Eur J Clin Pharmacol, 2005; 61:675-81.
7. Riechelmann RP, Zimmermann C, Chin SN, Wang L, Carroll AO, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage, 2008; 35:535-43.
8. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ, 1996; 154:1177-84.
9. Egger SS, Ratz AE, Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging, 2007; 24:429-40.
10. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Ther, 2008; 33:141-51.
11. Putnam KG, Buist DS, Fishman P, Andrade SE, Boles, et al. Chronic disease score as a predictor of hospitalization. Epidemiology, 2002; 13:340-6.
12. Tatro D. Drug Interaction Facts 2007: Facts and Comparisons. Wolters Kluwer Health Inc, St. Louis, USA, 2007.
13. Ramiarina RA, Ramiarina BL, Almeida RM, Pereira WC. Comorbidity adjustment index for the international classification of diseases, 10th revision. Rev Saude Publica, 2008; 42:590-7.
14. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol, 2003; 58:773-8.
15. Vonbach P, Dubied A, Krahenbuhl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med, 2008; 19:413-20.
16. Radosevic N, Gantumur M, Vlahovic-Palcevski V. Potentially inappropriate prescribing to hospitalised patients. Pharmacoepidemiol Drug Saf, 2008; 17:733-7.
17. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol, 2007; 63:709-14.
18. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm, 2004; 61:380-5.
19. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol, 2005; 56:286-90.
20. Terleira A, Portoles A, Rojas A, Vargas E. Effect of drug-test interactions on length of hospital stay. Pharmacoepidemiol Drug Saf, 2007; 16:39-45.
21. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology Drug Saf, 2007; 16:641-51.
22. Schneitman-McIntire O, Farnen TA, Gordon N, Chan J, Toy WA. Medication misadventures resulting in emergency department visits at and HMO medical center. Am J Health Syst Pharm, 1996; 53:1416-22.
23. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother, 2002; 36:1331-6.